Main Products/ Services/ Pipelines & Platforms
BRIM is a clinical-stage company developing novel peptide treatments for hard-to-treat diseases. BRIM’s first-in-class assets are based on its innovative stem cell regenerative PDSP technology platform, which has the potential to be effective in multiple therapy areas and indications: ▪ BRM421 - a phase 3 ready drug for Dry Eye Syndrome ▪ BRM424 - a phase 2 ready orphan drug for Neurotrophic Keratitis ▪ BRM521 - a preclinical drug for Osteoarthritis(OA)
Business Interests
We are looking for investment opportunities for our portfolio and seeking out-licensing or co-development partnership for the following assets: ▪ BRM421 - a phase 3 ready drug for Dry Eye Syndrome ▪ BRM424 - a phase 2 ready orphan drug for Neurotrophic Keratitis ▪ BRM521 - a preclinical drug for OA ▪ BRM132 - a phase 1 drug for NHL (non-Hodgkin lymphoma)
Contact Info
Yichun Maria Chen
VP of Business Development
+886-2-2659-8586#110
yichun.chen@brimbiotech.com
Yilun Chiang
Business Development Manager
+886-2-2659-8586#120
yichun.chen@brimbiotech.com